Table 3.
Transcript levels of prognosis gene markers in B cells of CLL patients before treatment with fludarabine.
| CLL-11 | CLL-2 | CLL-3R2 | CLL-4 | CLL-5 | CLL-6R2 | |
|---|---|---|---|---|---|---|
| ATM | 1.00 3 | 1.10 | 0.42 3 | 1.91 | 0.52 3 | 2.32 |
| BLM | 1.00 | 0.54 | 1.32 | 0.79 | 0.92 | 2.06 |
| CDK2AP1 | 1.00 | 0.52 | 2.59 | 0.33 | 0.70 | 1.75 |
| DCLRE1A | 1.00 | 1.26 | 2.84 | 0.12 | 1.27 | 3.11 |
| MYC | 1.00 | 1.36 | 20.33 4 | 0.95 | 1.42 | 34.39 4 |
| PCNA | 1.00 | 0.43 | 2.85 | 0.59 | 0.61 | 1.49 |
| SULF2 | 1.00 | 0.4 | 72.6 | 4.8 | 2.5 | 157.4 |
| TP53 | 1.00 | 0.94 | 0.04 5 | 1.12 | 0.70 | 0.62 5 |
| UMPS | 1.00 | 0.73 | 1.33 | 0.71 | 0.73 | 1.53 |
| XPC | 1.00 | 0.98 | 0.23 | 1.43 | 1.56 | 0.43 |
1 Ct values from this patient were used for normalization to compare expression levels between patients with the ΔΔCt calculation method.
2 Patient number followed by "R" indicates the refractoriness character to fludarabine.
3 A mono-allelic deletion on 11q22 was observed.
4 A gain on 8q was observed.
5 A mono-allelic deletion on 17p13 was observed.